Skip to content

Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports

Assessment of Complications, Quality of Life and Easiness of Use of Implantable Central Venous Access Ports : Cohort and Prospective Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00921141
Acronym
CCI
Enrollment
815
Registered
2009-06-16
Start date
2006-05-31
Completion date
2009-04-30
Last updated
2012-07-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Implantable central venous access ports, cancer

Brief summary

This is a prospective, descriptive and observational study of the anticancer center practice

Interventions

None listed

Sponsors

Centre Oscar Lambret
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with any cancer, requiring a central venous catheter * No contraindication for any surgery with local or complete anaesthesia

Exclusion criteria

* Previous Xylocaine or Lidocaine allergy * Clinic superior vena cava syndrome

Design outcomes

Primary

MeasureTime frame
Incidence and collection of complications for the patients requiring an implantable central venous access ports substitution/changeUntil the implantable central venous access ports removal

Secondary

MeasureTime frame
Brief description of the different risk factor for morbidityUntil the implantable central venous access ports removal
Assessment of the implantable central venous access ports ease-of-use for nurses according to the modalities of implementation and patient featuresUntil the implantable central venous access ports removal
Assessment of the patient quality of lifeBefore central venous access ports implementation, at the first day of chemotherapy, and during the cycle 4 of chemotherapy

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026